{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T16:30:17Z","timestamp":1787070617432,"version":"build-2736575974"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,10]]},"abstract":"<jats:sec>\n                    <jats:title>Aim:<\/jats:title>\n                    <jats:p>We aimed to determine the hormone receptor status in breast cancers and to investigate the relationship between single hormone receptor-positive, double hormone receptor-positive, double hormone receptor negativity, and human epidermal growth factor receptor 2 (HER2) status and some clinicopathological features.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>\n                      The study includes 85 patients who were diagnosed in our center between 2018 and 2019 and having surgical specimens were included in the study. Data of the cases, such as estrogen receptor (ER), progesterone receptor (PR), HER2 status, silver\n                      <jats:italic toggle=\"yes\">in situ<\/jats:italic>\n                      hybridization (SISH) evaluation results, age distribution, histopathological findings were recorded.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results and Conclusions:<\/jats:title>\n                    <jats:p>\n                      We investigated the relationship between age, grade, tumor size, lymph node metastases and ER, PR, and HER2. However, there was not a significant association between ER, PR, and HER2 and age, tumor size, lymph node metastases (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &gt; 0.05). On the other hand, we found a significant association between grades and ER (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.02) and PR (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.004), but not between grades and HER2 (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &gt; 0.05). High-grade tumors were tumors with the lowest ER, PR positivity rate. Considering the four subtypes, cases aged above 45 years were at most double hormone receptor-positive (75%) and ER-positive\/PR-negative (56%), respectively (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001). High-grade tumors were mostly double hormone receptor-negative and at least double hormone receptor positive. The ER-positive\/PR-negative subtype was between these two groups (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001). The increased tumor size (T3) and increased metastatic lymph node number (N2 and N3) were observed at least in the ER-positive\/PR-negative subtype. The majority of cases are in the older age group and invasive ductal carcinoma (IDC) is the most common tumor type. Older cases are most frequently double hormone receptor-positive and ER-positive\/PR-negative, respectively. The ER, PR positivity rate is low in high-grade tumors. ER-positive\/PR-negative tumors are of a higher grade than double hormone receptor-positive tumors, but they are of a lower grade than double hormone receptor-negative tumors. The increased tumor size and increased lymph node metastasis number are at most in the double hormone negative subtype and at least in the ER-positive\/PR-negative subtype. The ER-negative\/PR-positive subtype is observed very rarely, which raises the question of whether ER-negative\/PR-positive tumors really exist. Further studies are needed to investigate this subtype and its properties.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/ijpm.ijpm_606_20","type":"journal-article","created":{"date-parts":[[2024,5,30]],"date-time":"2024-05-30T04:19:44Z","timestamp":1717042784000},"page":"671-676","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":7,"title":["The hormone receptor status in breast cancer and the relationship of subtypes with clinicopathological features"],"prefix":"10.4103","volume":"64","author":[{"given":"Fatma","family":"Senel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-9-20240829","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3322\/caac.20107","article-title":"Global cancer statistics","volume":"61","author":"Jemal","year":"2011","journal-title":"CA Cancer J Clin"},{"key":"R2-9-20240829","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1200\/JCO.2003.09.099","article-title":"Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases","volume":"21","author":"Bardou","year":"2003","journal-title":"J Clin Oncol"},{"key":"R3-9-20240829","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/modpathol.2010.55","article-title":"Issues and updates: Evaluating estrogen receptor-alpha, progesterone receptor, and HER2 in breast cancer","volume":"23","author":"Allred","year":"2010","journal-title":"Mod Pathol"},{"key":"R4-9-20240829","doi-asserted-by":"crossref","first-page":"7721","DOI":"10.1200\/JCO.2005.09.004","article-title":"Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy","volume":"23","author":"Cui","year":"2005","journal-title":"J Clin Oncol"},{"key":"R5-9-20240829","doi-asserted-by":"crossref","first-page":"4772","DOI":"10.1200\/JCO.2007.12.2747","article-title":"Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype","volume":"25","author":"Rakha","year":"2007","journal-title":"J Clin Oncol"},{"key":"R8-9-20240829","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/bjc.1957.43","article-title":"Histological grading and prognosis in breast cancer; A study of 1409 cases of which 359 have been followed for 15 years","volume":"11","author":"Bloom","year":"1957","journal-title":"Br J Cancer"},{"key":"R10-9-20240829","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1200\/JCO.2013.50.9984","article-title":"Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology College of American Pathologists clinical practice guideline update","volume":"31","author":"Wolff","year":"2013","journal-title":"J Clin Oncol"},{"key":"R11-9-20240829","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1126\/science.3798106","article-title":"Human breast cancer: Correlation of relapse and survival with amplification of the HER-2\/neu oncogene","volume":"235","author":"Slamon","year":"1987","journal-title":"Science"},{"key":"R12-9-20240829","doi-asserted-by":"crossref","first-page":"412","DOI":"10.5306\/wjco.v5.i3.412","article-title":"Biological subtypes of breast cancer: Prognostic and therapeutic implications","volume":"5","author":"Yersal","year":"2014","journal-title":"World J Clin Oncol"},{"key":"R13-9-20240829","doi-asserted-by":"crossref","first-page":"55","DOI":"10.5858\/2010-0454-RAR.1","article-title":"HER2: Biology, detection, and clinical implications","volume":"135","author":"Gutierrez","year":"2011","journal-title":"Arch Pathol Lab Med"},{"key":"R15-9-20240829","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/j.1365-2559.1992.tb01032.x","article-title":"Pathological prognostics factors in breast cancer. II. Histological type. Relationship with survival in a large study with long-term follow-up","volume":"20","author":"Ellis","year":"1992","journal-title":"Histopathology"},{"key":"R16-9-20240829","doi-asserted-by":"crossref","first-page":"e0182397","DOI":"10.1371\/journal.pone.0182397","article-title":"Invasive lobular carcinoma of the breast: A special histological type compared with invasive ductal carcinoma","volume":"12","author":"Zheling","year":"2017","journal-title":"PLoS One"},{"key":"R17-9-20240829","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1093\/annonc\/mdv221","article-title":"Panel Members. Tailoring therapies: Improving the management of early breast cancer: St Gallen International Expert Consensus on the primary therapy of early breast cancer","volume":"26","author":"Coates","year":"2015","journal-title":"Ann Oncol"},{"key":"R18-9-20240829","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1200\/JCO.2003.03.088","article-title":"Incidence of invasive breast cancer by hormone receptor status from 1992 to 1998","volume":"21","author":"Li","year":"2003","journal-title":"J Clin Oncol"},{"key":"R19-9-20240829","doi-asserted-by":"crossref","first-page":"28","DOI":"10.3322\/canjclin.47.1.28","article-title":"Tumor-related prognostic factors for breast cancer","volume":"47","author":"Donegan","year":"1997","journal-title":"CA Cancer J Clin"},{"key":"R20-9-20240829","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1002\/1097-0142(19911101)68:9<1918::AID-CNCR2820680913>3.0.CO;2-L","article-title":"Reappriasal of internal mammary node metastases as a prognostic factor in patients with breast cancer","volume":"68","author":"Noguchi","year":"1991","journal-title":"Cancer"},{"key":"R21-9-20240829","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1038\/modpathol.3800229","article-title":"Progesterone receptor by immunohistochemistry and clinical outcome in breast cancer: A validation study","volume":"17","author":"Mohsin","year":"2004","journal-title":"Mod Pathol"},{"key":"R23-9-20240829","first-page":"e1918160","article-title":"Clinicopathological characteristics and breast cancer\u2013specific survival of patients with single hormone receptor\u2013positive breast cancer","volume":"3","author":"Li","year":"2020","journal-title":"JAMA"},{"key":"R24-9-20240829","doi-asserted-by":"crossref","first-page":"3324","DOI":"10.1200\/JCO.2007.14.2471","article-title":"Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression","volume":"26","author":"Anders","year":"2008","journal-title":"J Clin Oncol"},{"key":"R25-9-20240829","doi-asserted-by":"crossref","first-page":"133","DOI":"10.4038\/cmj.v52i4.916","article-title":"Hormone receptor expression and Her\/2neu amplification in breast carcinoma in a cohort of Sri Lankans","volume":"52","author":"Ratnatunga","year":"2007","journal-title":"Ceylon Med J"},{"key":"R26-9-20240829","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/BF01806938","article-title":"Oestrogen and progesterone receptor content and the distribution of histological grade in breast cancer","volume":"2","author":"Thoresen","year":"1982","journal-title":"Breast Cancer Res Treat"},{"key":"R27-9-20240829","first-page":"105","article-title":"Invasive lobular carcinoma of breast histopathological subtypes: Clinicopathological study","volume":"6","author":"Jagtap","year":"2016","journal-title":"Int J Health Sci Res"},{"key":"R28-9-20240829","doi-asserted-by":"crossref","first-page":"3868","DOI":"10.1200\/JCO.2005.05.203","article-title":"It is not time to stop progesterone receptor testing in breast cancer","volume":"23","author":"Colomer","year":"2005","journal-title":"J Clin Oncol"},{"key":"R29-9-20240829","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/S0140-6736(11)60993-8","article-title":"Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: Patient-level metaanalysis of randomised trials","volume":"378","author":"Davies","year":"2011","journal-title":"Lancet"},{"key":"R30-9-20240829","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1309\/4WV79N2GHJ3X1841","article-title":"Immunohistochemistry of estrogen and progesterone receptors reconsidered: Experience with 5,993 breast cancers","volume":"123","author":"Nadji","year":"2005","journal-title":"Am J Clin Pathol"},{"key":"R31-9-20240829","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1200\/JCO.2007.14.8411","article-title":"Does estrogen receptor negative\/progesterone receptor positive breast carcinoma exist?","volume":"26","author":"De Maeyer","year":"2008","journal-title":"J Clin Oncol"},{"key":"R32-9-20240829","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.1200\/JCO.2009.25.6529","article-title":"American Society of Clinical Oncology\/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer","volume":"28","author":"Hammond","year":"2010","journal-title":"J Clin Oncol"},{"key":"R33-9-20240829","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ctrv.2018.05.005","article-title":"Estrogen receptor\u2013negative progesterone receptor\u2013positive breast cancer: \u201cNobody's land\u201d or just an artifact?","volume":"67","author":"Kunc","year":"2018","journal-title":"Cancer Treat Rev"},{"key":"R35-9-20240829","first-page":"673","article-title":"Correlation of HER-2\/neu protein overexpression with other prognostic and predictive factors in invasive ductal breast cancer","volume":"21","author":"Ivkovic-Kapicl","year":"2007","journal-title":"In Vivo"},{"key":"R36-9-20240829","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1136\/jcp.2004.022772","article-title":"Association between tumour characteristics and HER-2\/neu by immunohistochemistry in 1362 women with primary operable breast cancer","volume":"58","author":"Huang","year":"2005","journal-title":"J Clin Pathol"},{"key":"R37-9-20240829","doi-asserted-by":"crossref","first-page":"38","DOI":"10.5146\/tjpath.2012.01095","article-title":"Correlation of hormone receptors with Her-2\/neu protein expression and the histological grade in invasive breast cancers in a cohort of Saudi Arabia","volume":"28","author":"Arafah","year":"2012","journal-title":"Turk J Pathol"}],"container-title":["Indian Journal of Pathology and Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/IJPM.IJPM_606_20","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:32:42Z","timestamp":1787067162000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/IJPM.IJPM_606_20"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.4103\/ijpm.ijpm_606_20","relation":{},"ISSN":["0377-4929"],"issn-type":[{"value":"0377-4929","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]}}}